Key Points
- NeurAxis CFO Timothy Robert Henrichs purchased 7,593 shares at an average price of $1.96 per share (totaling $14,882.28) on April 1, a transaction disclosed in an SEC filing that leaves him owning 7,593 shares.
- Analyst Craig Hallum raised its price target on NeurAxis from $8.00 to $13.00 and assigned a "buy" rating; MarketBeat data shows a consensus rating of "Buy" with a $13.00 consensus price target.
- For context, NeurAxis stock opened at $7.25, has a market cap of about $81.1 million, a 12‑month range of $1.33–$7.97, a negative P/E, and 50/200-day moving averages of $5.80 and $4.15 respectively.
NeurAxis, Inc. (NASDAQ:NRXS - Get Free Report) CFO Timothy Robert Henrichs bought 7,593 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were purchased at an average cost of $1.96 per share, for a total transaction of $14,882.28. Following the completion of the purchase, the chief financial officer owned 7,593 shares in the company, valued at approximately $14,882.28. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
NeurAxis Price Performance
Shares of NeurAxis stock opened at $7.25 on Friday. The stock has a market cap of $81.11 million, a PE ratio of -3.94 and a beta of 2.49. The business has a fifty day simple moving average of $5.80 and a 200-day simple moving average of $4.15. NeurAxis, Inc. has a 12 month low of $1.33 and a 12 month high of $7.97.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the business. State Street Corp acquired a new stake in shares of NeurAxis in the 4th quarter valued at $139,000. Money Concepts Capital Corp acquired a new position in NeurAxis during the third quarter worth $103,000. Citadel Advisors LLC increased its position in NeurAxis by 39.6% during the third quarter. Citadel Advisors LLC now owns 35,627 shares of the company's stock worth $110,000 after buying an additional 10,103 shares during the last quarter. Manatuck Hill Partners LLC bought a new position in NeurAxis during the second quarter valued at about $122,000. Finally, Geode Capital Management LLC raised its holdings in NeurAxis by 48.8% during the fourth quarter. Geode Capital Management LLC now owns 75,653 shares of the company's stock valued at $343,000 after buying an additional 24,817 shares in the last quarter. Institutional investors own 11.77% of the company's stock.
Analysts Set New Price Targets
Separately, Craig Hallum upped their target price on NeurAxis from $8.00 to $13.00 and gave the company a "buy" rating in a report on Friday, March 20th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $13.00.
Get Our Latest Stock Analysis on NRXS
NeurAxis Company Profile
(
Get Free Report)
NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.
NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
